AlphaMark Advisors’s Zimmer Biomet ZBH Stock Holding History

AlphaMark Advisors’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$42K	Sell	395 -550	-58%	-$59K	0.02%	260
2024 Q3	$102K	Sell	945 -45	-5%	-$4.91K	0.04%	275
2024 Q2	$107K	Hold	990	–	–	0.04%	277
2024 Q1	$131K	Buy	990 +940	+1,880%	+$117K	0.05%	250
2023 Q4	$6K	Sell	50 -75	-60%	-$8.37K	﹤0.01%	580
2023 Q3	$14K	Hold	125	–	–	0.01%	474
2023 Q2	$18K	Hold	125	–	–	0.01%	332
2023 Q1	$16K	Hold	125	–	–	0.01%	354
2022 Q4	$16K	Hold	125	–	–	0.01%	326
2022 Q3	$13K	Hold	125	–	–	0.01%	388
2022 Q2	$13K	Hold	125	–	–	0.01%	372
2022 Q1	$16K	Buy	+125	New	+$15.1K	0.01%	361
2018 Q3	–	Sell	-185	Closed	-$20K	–	545
2018 Q2	$20K	Buy	+185	New	+$20.1K	0.01%	297

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

AlphaMark Advisors's ZBH Position: Q4 2024 in Review

AlphaMark Advisors reduced its Zimmer Biomet (ZBH) stake by 58% in Q4 2024, selling an estimated $59K and leaving 395 shares worth $42K. The position accounts for 0.02% of the portfolio, ranked #260.

AlphaMark Advisors first reported a position in ZBH in Q2 2018 and has held it in 13 quarters since. The position peaked at $131K in Q1 2024. 1,028 funds tracked by Wall St. Rank hold ZBH as of Q4 2024.

AlphaMark Advisors held 395 shares of Zimmer Biomet worth $42K as of Q4 2024.
AlphaMark Advisors sold 550 Zimmer Biomet shares in Q4 2024, an estimated $59K.
Zimmer Biomet made up 0.02% of AlphaMark Advisors's portfolio in Q4 2024, its #260 holding.
AlphaMark Advisors first reported a position in Zimmer Biomet in Q2 2018 and has held it in 13 quarters since.
AlphaMark Advisors's Zimmer Biomet position peaked at $131K in Q1 2024.
1,028 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.